Answers are grounded in this paper and cite their sources.
Case report reveals repaglinide-induced immune hemolytic anemia in a patient with type 2 diabetes, highlighting the need for hematological vigilance with meglitinides.
Background: Drug-induced immune hemolytic anemia (DIIHA) is a rare adverse drug reaction occurring in approximately 1-2 cases per million persons per year.Over 130 drugs have been implicated, but meglitinide-class antidiabetic agents have not previously been reported as causative.Case presentation: A 54-year-old man with type 2 diabetes presented with progressive fatigue, icterus, and dark urine 6 weeks after repaglinide 2 mg thrice daily was added to his stable metformin regimen.Investigations confirmed hemolytic anemia (hemoglobin 7.4 gm/dL, reticulocytosis 8.2%, lactate dehydrogenase (LDH) 684 U/L, indirect bilirubin 3.6 mg/dL, and spherocytes on smear) with a strongly positive direct antiglobulin test (DAT) (3+).Autoimmune, infective, and lymphoproliferative etiologies were excluded.Repaglinide was discontinued and sitagliptin substituted.Without corticosteroids or transfusion, hemoglobin recovered to 12.6 gm/dL and DAT normalized over 8 weeks.Conclusion: This is the first published case of repaglinide-induced DAT-positive hemolytic anemia, with causality graded probable by both the Naranjo scale (score 6) and World Health Organization-Uppsala Monitoring Centre (WHO-UMC) system.Only two prior signals exist in VigiBase.This report expands the spectrum of antidiabetic drug-associated DIIHA and underscores the need for hematological vigilance with meglitinides.
No takes yet. Share an insight, caveat, or question.
Garg et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: